Instem plc Result of AGM (3751O)

TIDMINS

RNS Number : 3751O

Instem plc

09 June 2022

Instem plc

("Instem" or the "Company")

Result of AGM

Instem (AIM: INS.L), a leading provider of IT solutions to the global life sciences market, announces that at its Annual General Meeting held today, all resolutions were duly passed. The results of the proxy voting position received in advance of the meeting are reported below:

 
 No.   Resolution              For          % For     Against     % Against   Withheld 
       Accounts and 
 01     Reports                13,886,707   89.98%    1,545,989   10.02%      2,094,614 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Re-elect R 
 02     A Bandali              17,527,120   100.00%   190         0.00%       0 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Re-elect D 
 03     M Sherwin              13,727,503   88.95%    1,705,343   11.05%      2,094,464 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Re-elect M 
 04     F McGoun               13,566,252   87.91%    1,866,594   12.09%      2,094,464 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Re-appoint 
 05     Auditors               17,527,120   100.00%   190         0.00%       0 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
 06    Auditors Remuneration   17,527,310   100.00%   0           0.00%       0 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
 07    Allot Shares            16,989,283   96.93%    538,027     3.07%       0 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Allot Equity 
 08     Securities             16,989,283   96.93%    538,027     3.07%       0 
      ----------------------  -----------  --------  ----------  ----------  ---------- 
       Make Market 
 09     Purchases              17,527,310   100.00%   0           0.00%       0 
      ----------------------  -----------  --------  ----------  ----------  ----------

Notes:

-- The full text of each of the resolutions is contained in the Notice of Annual General Meeting dated 16 May 2022, which is available on the Company's website at https://www.instem.com .

-- Proxy appointments which gave discretion to the Chairman of the AGM have been included in the "For" total for the appropriate resolution.

-- A "Withheld" vote is not a vote in law and is not counted in the calculation of the proportion of the votes cast "For" or "Against" a resolution.

-- The issued share capital of the Company as at 09 June 2022 was 22,676,808 ordinary shares of 10p each. No shares are held in treasury.

For further information, please contact:

 
 Instem plc                               Via Walbrook 
 Phil Reason, CEO 
 Nigel Goldsmith, CFO 
 
 Singer Capital Markets (Nominated 
  Adviser & Broker)                       +44 (0) 20 7496 3000 
 Peter Steel 
  Alex Bond 
  Rachel Hayes 
 
 Stifel Nicolaus Europe Limited (Joint 
  Broker)                                 +44 (0) 20 7710 7600 
 Ben Maddison 
 Alex Price 
 
 Walbrook Financial PR                    +44 (0) 20 7933 8780 
 Tom Cooper                               instem@walbrookpr.com 
 Nick Rome

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

   To learn more about Instem solutions and its mission, please visit   www.instem.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGSSWFLUEESEIM

(END) Dow Jones Newswires

June 09, 2022 11:01 ET (15:01 GMT)

Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024